anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a foamable solid dosage form for the administration of an intended ingredient to children who can not swallow a tablet or debilitated patients.  &lt;P&gt;SOLUTION: This foamable solid dosage form has the form of a tablet having a size and a shape suitable for oral administration and comprises a foamable disintegrator activated by water or saliva and a medicinal ingredient. The foaming disintegration occurs as the result of generation of carbon dioxide gas from the reaction of a soluble acid source with an alkali metal carbonate or carbonate source. The soluble acid source includes e.g. an edible acid such as citric acid or tartaric acid. The carbonate source includes e.g. sodium bicarbonate or potassium bicarbonate. The amount of the foamable disintegrator effective for aid for the rapid (preferably within 30 sec to 7 min) and complete disintegration of the tablet when orally administered is preferably 5-50 wt.%.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Disseminated intravascular coagulation (DIC) is a syndrome caused by the activation of blood coagulation, in which systemic intravascular micro thromboses result in multiple organ failure and severe bleeding due to consumption of platelets and coagulation factors \[1\]. Compared with adults, neonates have an immature coagulation-fibrinolysis system and are prone to complications that cause DIC, such as hypoxia, acidosis, and infection \[2\]. Additionally, preterm infants have a lower hemostatic profile than term infants, which increases their risk of DIC \[3\]. However, gold standard interventions and treatments for DIC are lacking in neonatal medicine, Veldman et al. suggested that DIC in neonates is caused by prenatal risk factors such as placental abruption (PA), pregnancy induced hypertension (PIH), and neonatal factors such as sepsis, asphyxia, and interventricular hemorrhage (IVH), along with postnatal factors, such as necrotizing enterocolitis, gastrointestinal perforation, and infection \[4\]. The Japan Society of Obstetrical, Gynecological \&amp; Neonatal Hematology (JSOGNH) revised its diagnostic guidelines for neonatal DIC in 2016 and proposed a DIC scoring system \[5\]. Anticoagulant therapy, such as antithrombin administration and fresh frozen plasma (FFP), has been used to treat neonatal DIC \[6\]. Since 2008, recombinant human soluble thrombomodulin (rTM) has emerged as a novel anticoagulant for DIC in Japan \[7\]. Reversal of the underlying condition is paramount in achieving treatment success in the newborn with DIC. Strategies such as early antibiotic therapy and identification and control of the source of disease in cases of necrotizing enterocolitis, sepsis, and septic shock should always precede interventions directed at normalizing the coagulation system \[8\]. reports are lacking about diseases associated with neonatal DIC and whether anything predicts mortality in this context. We discuss the clinical andlaboratory criteria using (JSOGNH) scoring system to see if DIC score could predict mortality in neonates.
PURPOSE:To enhance the feeling under usage and to improve the safety and usable period by blending 0.2-5wt% polymolecular chain emulsifier whose HLD is &lt;=9 to prepare the emulsifying composition containing powder and soap. CONSTITUTION:A polyhydric alcohol having &gt;=3 hydroxy radicals in one molecule and ester ethylene oxide of higher fatty acid are subjected to an addition reaction to obtain polymolecular chain emulsifier whose HLB is &gt;=9. This polymolecular chain emulsifier includes polyoxyethylene hardened castor oil ether, polyoxyethylene glyceryl fatty acid ester, etc. 0.2-5wt% of the above- described polymolecular chain emulsifying agent is blended with about 1-20wt% powder and about 0.5-5wt% soap to prepare the emulsifier agent. This powder is an inorganic powder such as titanium oxide, kaolin, etc. or an organic powder such as crystalline cellulose, nylon powder, etc.
PURPOSE:An inhibitor for dandruff capable of preventing a scurfy disease of the scalp (dandruff disease) and urtication caused by it by administration to the affected part, and thoroughly satisfactory with respect to safety, stability of pharmaceutical manufacturing, smell, etc., comprising an antagonist of a histamine H2 acceptor as an active ingredient. CONSTITUTION:An inhibitor for dandruff, e.g., a medicine for hair and/or scalp, shampoo, hair dressing, etc., comprising ordinarily &gt;=0.5wt% preferably 1-20wt% antagonist of a histamine H2 acceptor, e.g., cimetidine, metiamide, burimamide, ranitidine, etc. as an active ingredient. The use of the inhibitor for dandruff according to a conventional way can prevent thoroughly dandruff and urtication caused by it. The antagonist of a histamine H2 acceptor is extremly stable in a solvent, e.g., water, an alcohol, etc. and is excellent with respect to safety and smell. It can be used together with a conventional inhibitor for dandruff, especially germicide, and in this case better results can be obtained.
In the prepn., (a) a dil. aq. soln. of the mucoprotide components is produced by autolysis of the starting material, precipitating precipitable proteins with dilute lead acetate and dilute ammonium sulphate, and sepn. of the supernatant; (b) the aq. soln. is treated with acetone to form 3 layers; (c) the upper and middle layers are sepd. from the lower layer; (d) the two upper layers from (c) are heated to ppte unstable and antigenic substances; and (e) the ppte is sepd. off and discarded. A new mucoprotide prod. is produced from liver parenchyma, placenta, yeast or other natural sources and chiefly consists of protides such as protein and protein hydrolysates with a ca. 0.1-40% mucoid content. The mucoprotide shows a marked saddle in the IR spectrum at a wave number between ca. 1000 and 1200. T&#39;e mucoprotide product is useful for the treatment of Allergies and hypersensitivities, toxic states, undesired side-effects of drugs, drug-dependence and alcoholism. It is particularly useful when the disorder to be treated is accompanied or caused by damaged liver function. The product may be administered orally or parenterally.
This information processing system comprises a portable terminal. The portable terminal detects sensor information for assessing a user&#39;s emotions. It would be permissible, as an example, for the sensor information to be sound information which is detected by a microphone, or image information which is captured by a camera. The information processing system assesses the user&#39;s emotions on the basis of the sensor information. The portable terminal detects the sensor information in a period when the said portable terminal is in a standby state. As an example, the said standby state is a state wherein a display of the portable terminal is off.
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a hair grower which has good preparation stability, is free from problems such as undesired side effects and scalp irritation, and can exhibit an excellent hair-growing effect.  &lt;P&gt;SOLUTION: This hair grower comprises one or more extracts selected from the extracts of Lentinus edodes (Berk.) Singer ; Echinacea angustifolia DC. or Echinacea purpurea Moench, Prunus domestica Lind., bean sprout (excluding adlay sprout), and Gynostemma pentaphyllum (Thunb.) Makino, which have high vascular endothelial cell growth factor (VEGF) production-promoting effects. Consequently, the hair grower induces revascularization on the peripheries of hair follicles to promote the transfer from the resting stage of the hair follicles to the growth stage or extend the growth stage of the hair follicles, thereby capable of giving the excellent hair-growing effect.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
1513715 Xylitol-coated confectionery P FERRERO &amp; C SpA 7 March 1977 [5 March 1976] 9587/77 Heading A2B [Also in Division A5] Confectionery dragees are coated with an intimate mixture of 0.5-15, preferably 1-2, wt. parts normally solid fatty substance and 100 wt. parts (as anhydrous) xylitol. The fatty substance may comprise mono-, di- and triglycerides of palmitic, oleic and stearic acid, e.g. cocoa butter. The coating may include an emulsifier and thickener and may be applied as an aqueous solution with the fatty substance in molten state. Anchoring gum layers may be present. Suitable substrates are listed and may include sweeteners.
Soluble regulators such as growth factors and differentiation factors are used to treat disc disease and herniation. Such substances may be produced with recombinant genetic techniques, or obtained from animal sources. In the preferred embodiment the materials are concentrated from a patient&#39;s blood then injected into the epidural space of the spinal canal and or the intervertebral disc using techniques well known to those skilled in the art. The blood is centrifuged to obtain platelets, and the platelets release the soluble regulators/growth factors by adding a mixture of calcium chloride and topical bovine thrombin. According to one example, 6ml of platelet rich plasma is combined with 1 ml of the calcium chloride—thrombin mixture and injected into the disc or spinal canal. Alternatively, the platelet rich plasma and calcium chloride—thrombin mixture may be injected separately. Soluble regulators obtained from other sources or different amounts of the platelet rich plasma than described above could also be used.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a direct dye having excellent dyeing characteristics.  &lt;P&gt;SOLUTION: The asymmetric disazo compound contains a 2-pyridinium group and a cationic or a non-cationic linker. A dyeing composition comprises the compound as a direct dye in a medium appropriate for dyeing keratin fibers. A method for coloring the keratin fibers comprises employing the composition. A device has a plurality of compartments.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain a filter material, useful for blood transfusion and usable for removing leukocytes from the whole blood or an erythrocytic pharmaceutical by introducing acidic functional groups into a nonwoven fabric, a woven fabric or a polymer porous substance. CONSTITUTION:The objective filter material is obtained by introducing one or more acidic functional groups (e.g. carboxyl, phosphoric acid or phenol) into a nonwoven fabric, a woven fabric or a polymer porous substance (e.g. polyvinyl formal) having open cells according to a method for radiation grafting, etc. The porosity of the polymer porous substance is 45-95% and the density of the acidic functional groups in the material is 0.05-5mequiv./m&lt;2&gt; based on the surface area of the filter material. Leukocytes can be removed at a higher level than that of a filter material without any acidic functional groups and a lower leukocyte residual ratio can be achieved for blood after filtration. The filter material is suitable for treating collagen disease, leukemia, etc., and extracorporeal circulation type removal of the leukocytes.
Relatively stable supersaturated solutions of calcium gluconate for therapeutic purposes, for example, for intramuscular injections, are obtained by dissolving in a hot concentrated solution of calcium gluconate suitable amounts of calcium salts of polyoxymonocarboxylic acids derived from aldodisaccharoses, for example, calcium maltobionate or calcium lactobionate or mixtures thereof, introducing the hot solutions into suitable containers, and closing the latter hermetically before crystallization sets in.  The containers may be further heated, once or repeatedly, until on cooling and shaking the solution remains clear.  The solutions may contain other therapeutically valuable substances, such as the compounds mentioned in Specification 332,840, [Class 81 (i), Disinfecting &amp;c.], including salts of the alkali and alkaline-earth and heavy metals, alkaloids, therapeutically useful dyestuffs, natural glucosides, and local an sthetics.  Examples are given.  Specification 359,862 also is referred to.ALSO:Relatively stable supersaturated solutions of calcium gluconate for therapeutic purposes, for example for intramuscular injection, are obtained by dissolving in hot concentrated solutions of calcium gluconate suitable amounts of calcium salts of polyoxymonocarboxylic acids derived from aldodisaccharoses, for example, calcium maltobionate or calcium lactobionate or mixtures thereof, introducing the hot solutions into suitable containers, and closing the latter hermetically before crystallization sets in.  The containers may be further heated, once or repeatedly, until on cooling and shaking the solution remains clear.  The solutions may contain other therapeutically valuable substances, such as the compounds mentioned in Specification 332,840, [Class 81 (i), Disinfecting &amp;c.], including salts of the alkali and alkaline earth and heavy metals, alkaloids, therapeutically useful dyestuffs, natural glucosides, and local an sthetics.  Examples are given.  Specification 359,862 also is referred to.
PURPOSE:To control viscosity as desired without degrading the emulsion stability of an emulsion type base material by adding a specific range of ethanol to said material. CONSTITUTION:&#39;&#39;Lauromacrogol  &#39;&#39; and stearic monoglyceride are used for emulsifiers, and fatty acids, higher alcohols, vegetable oils, etc. are used for fatty components. Propylene glycol, sorbitol, polyhydric alcohols, refined water, etc. are used for water soluble components, and 0-5w/w% ethanol is added to these. In this time, the amt. of the ethanol to be added is changed, whereby the emulsion type base material of an arbitrary viscosity is obtained without degrading the emulsion stability of the base material.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for complex minimally invasive treatment of abdominal abscesses. That is ensured by drainage of the abscess cavity under ultrasound control, irrigation and aspiration of cavity with 0.9 % sodium chloride solution. Volume of evacuated exudate is determined from an abscess cavity. Cavity is irrigated and aspirated by 0.9 % sodium chloride three times. Thereafter, a photosensitizer &#34;Photosens®&#34; is introduced into the pathological focus in dilution in dose of 2 mg/ml with 0.9% sodium chloride in an amount equal to the volume of initially evacuated exudate. After 30 minutes, the photosensitizer solution is aspirated. Fluoroplastic fiber with diameter of 400 mcm etched at end with 40 % hydrofluoric acid is introduced through the mounting cannula into the abscess cavity. Performing laser irradiation of cavity for 30 minutes with power of continuous radiation of 180 mWt, power density of laser radiation at fiber end is 1.4 Wt/cm.EFFECT: method provides reduced level of endogenous intoxication in earlier terms, reduced time of obtaining negative bacteriological culture, earlier clinical improvement of patients.1 cl, 1 tbl, 2 ex
Biodegradable neurotoxin implants and methods of malting and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient&#39;s body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient&#39;s body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.
1,191,385. Hydroxybenzothioxanhene derivatives. MERCK &amp; CO. Inc. 24 April, 1968 [27 April, 1967], No. 51489/69. Divided out of 1,191,384. Heading C2C. Novel hydroxybenzothioxanthene derivatives of the general formula wherein B is a benzene ring fused in the [a] or [c] position, X is a bromine or chlorine atom and each R is a hydrogen atom or a C 1-6  alkyl group, are prepared by reaction of a benzothioxanthenone derivative of the general formula with a Grignard reagent of the general formula hal.Mg.CH 2 CH 2 CH 2 .N(R) 2 , wherein hal is a halogen atom, and hydrolysis of the resulting Grignard adduct. Benzothioxanthenone derivatives of the second general formula above are prepared by heating a naphthylthiobenzoic acid derivative of the general formula in the presence of a dehydrating agent of the polyphosphoric acid type. 5 - Chloro - 2 - (1 - or 2 - naphthylthio) benzoic acid is prepared by treatment of 5-chloroanthranilic acid with nitrous acid, followed by potassium iodide, and reaction of the resulting 2-iodo-5- chlorobenzoic acid with α- or #-naphthalenethiol, respectively.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tablet having high adhesion between an outer shell and an inside area and scarcely causing crack or peeling.  &lt;P&gt;SOLUTION: This tablet 1 is formed by integrally molding the inside area 3 formed by applying compression molding to powder components, with the outer shell 2 containing components different from the powder. The outer shell 2 is formed of component melting by ultrasonic vibration. Preferably, the outer shell 2 and the inside area 3 are integrally molded while applying the ultrasonic vibration. This tablet 1 is manufactured by filling a tablet molding die with mixture including raw material powder, and compressing the mixture while applying ultrasonic vibration thereto via molding pestle. In prior to filling the die with the mixture, a melting component is attached to the inside of the die and the surface of the molding pestle by the ultrasonic vibration.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Systems, methods, and instrumentalities may be configured for managing infant health. An example system may communicate with a user device to collect and assess infant health metrics and parental usage. The system may configure a health trajectory for the infant by analyzing parental compliance and aggregate health data for generating an intervention data set. Interventions may be sent to the user device based on projected benefits and encouraging parental action. Health metrics may modify the health trajectory and interventions based on the infant&#39;s development and parental engagement. The system may monitor user compliance such that interventions are presented to maximize completion likelihood.
PROBLEM TO BE SOLVED: To prevent the wastage of a domestic animal by reinforcing immune activity, preventing infections disease such as a cold and also protecting stress by feeding an oil and fat-coated vitamin C to the domestic animal. SOLUTION: This method for protecting the wastage of a domestic animal is provided by feeding (A) 5-50 (g/day head) oil and-fat-coated vitamin C, and preferably (B) 1-20 (g/day head) chromium yeast and (C) 10-500 (g/day head) theriac for reinforcing immune activity, preventing infectious disease such as a cold, protecting stress and improving the amount of eating of a feed. The oil and fat of the component A is a hardened oil and fat and especially a hardened soybean oil and fat is preferable. The heardened oil and fat preferably has &lt;=5 acid value, &lt;=3 iodine value and 60-65 deg.C melting point. The component B is a beer yeast and contains 1,000-1,600 ppm non-toxic trivalent chromium. Also it is preferable to use 10-100 pt.wt. coating oil and fat based on 100 pts.wt. vitamin C.
PURPOSE:To obtain an admixture for cosmetics, showing an entirely new opal- like color, having a high-grade visual appearance and excellent in optical stability of the opal-like color by blending a silica fine powder prepared by deionization of silica sol. CONSTITUTION:This cosmetic is obtained by blending silica fine particles, especially having &lt;=0.70mum average particle size and &lt;=15% variation coefficient of particle diameter in an amount of &lt;=20vol.% on SiO2 base. As the silica fine particle, one having &lt;=560muS/cm conductivity is preferably used. In this cosmetic, a silica suspension prepared by dispersing the silica fine particles in water or an organic solvent and then deionizing the resultant silica sol according to the ion-exchange treatment (The treatment is carried out till the conductivity of the silica sol reaches about &lt;=560muS/cm) and exhibiting a stabilized colloidal dispersion state is used. Thereby, a color peculiar to opal is shown. The silica suspension is useful as an admixture for a toilet water, a milky lotion, etc.
PURPOSE:To obtain a plaster sheet for skin by laminating a vinyl chloride resin film to a polyethylene terephthalate film, successively forming 1st and 2nd primer layers on the surface of the polyethylene terephthalate layer of the obtained composite film and forming a tacky adhesive layer containing an agent on the primer layers. CONSTITUTION:A 1st primer layer is formed on the surface of a polyethylene terephthalate layer of a composite film produced by laminating a soft vinyl chloride resin film to a polyethylene terephthalate film. A 2nd primer layer is formed on the 1st primer layer and a tacky adhesive layer composed of a styrene-diene-styrene block copolymer is laminated and bonded to the 2nd primer layer to obtain a sheet for applying to the skin. The 1st primer layer is composed of a composition produced by compounding a polyurethane having OH terminals with a saturated polyester resin, an ethylene-vinyl acetate copolymer, a chlorinated rubber and fine powder of anhydrous silica. The 2nd primer layer is formed by the gravure-coating of a mixture same as the 1st primer layer. The thickness of the polyethylene terephthalate film used in the substrate is &lt;=10mum.
FIELD: microbiology, antibiotics. SUBSTANCE: antibiotic &#34;ВМУ&#34;-46164 isolated from fermentation product of the strain Actinomadura ATCC 53806 has empirical formula C 40 H 43 N 2 O 12 C, molecular mass 778 and shows antitumor activity. Method of antibiotic preparing involves fermentation of the strain-producer, filtration of cultural fluid, mixing filtrate with DEAE-cellulose. Mixture is cooled, DEAE-cellulose is separated by filtration, washed its with buffer and extracted with mixture of organic substances. Extract is filtered, sorbent is washed with organic solvent, filtrates were combined, water is added. Organic layer is separated and concentrated followed by isolation and purification of the end product. EFFECT: improved method of antibiotic producing and purification. 4 cl, 4 dwg, 2 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a compounded composition which improves the antimicrobial disinfectant actions of a cationic surfactant having antimicrobial disinfectant actions, realizes effective antimicrobial disinfectant actions in a low concentration, and is highly safe for skins, eyes, and the like.  &lt;P&gt;SOLUTION: The compounded composition comprises a specific cationic surfactant having antimicrobial disinfectant actions and a specified nonionic surfactant. The weight concentration of the cationic surfactant is preferably 0.1 to 5.0 ppm, and the amount of the nonionic surfactant is preferably ≥3 pts.wt. per pt.wt. of the cationic surfactant.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT